XTalks
AUGUST 22, 2022
The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. What clinical value does this expanded clearance provide?
The Pharma Data
JANUARY 20, 2021
Teerlink is actively involved in many acute and chronic heart failure clinical trials, serving on endpoint, data safety monitoring, and steering committees for numerous international cardiovascular studies. Dr. Teerlink was profiled in The Lancet as an internationally recognized leader in heart failure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 4, 2020
Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. This press release and further information about Alexion can be found at: www.alexion.com. Forward-Looking Statement.
The Pharma Data
MARCH 31, 2023
FortiHFy includes trials across the spectrum of HF, such as PARADIGM-HF, PIONEER-HF, PANORAMA-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan 4,5.
The Pharma Data
AUGUST 30, 2021
Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). In three clinical trials, patients taking Leqvio maintained LDL-C reduction throughout each six-month dosing interval 8,10. In the first analysis, patients with established CeVD treated with Leqvio achieved an average 55.2%
XTalks
FEBRUARY 8, 2024
According to AstraZeneca, the drug had strong demand across all of its approved indications and was further supported by recent guideline updates from cardiology societies. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials. billion in 2022.
The Pharma Data
JANUARY 12, 2021
Dosing is underway in Phase 3 trials of ULTOMIRIS in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), ALXN2060 (AG10) in ATTR cardiomyopathy in Japan , CAEL -101 in AL amyloidosis and ALXN2040 in paroxysmal nocturnal hemoglobinuria (PNH) patients with extravascular hemolysis (EVH).
Expert insights. Personalized for you.
111 
Let's personalize your content